Zobrazeno 1 - 10
of 256
pro vyhledávání: ''
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
Liisa M. Pelttari, Paula Poikonen-Saksela, Kristiina Aittomäki, Päivi Auvinen, Arja Jukkola-Vuorinen, Sanna Hallamies, Heli Nevanlinna, Johanna Mattson, Carl Blomqvist, Antti Jekunen
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-5 (2017)
BMC Cancer
BMC Cancer
Background Several susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4819e7805611ab5361165ecad3b1625
https://erepo.uef.fi/handle/123456789/5171
https://erepo.uef.fi/handle/123456789/5171
Autor:
Jan Steffen, Michalina Dabrowska, Aneta Balabas, Magdalena Piatkowska, Dorota Nowakowska, Izabela Brozek, Anna Niwińska, Magdalena Ratajska, Jadwiga Rachtan, Janusz Limon, Anna Kluska
Publikováno v:
Familial Cancer
It is estimated that about 5–10% of ovarian and 2–5% of all breast cancer patients are carriers of a germline BRCA1 or BRCA2 gene mutation. Most families with detected BRCA1 or BRCA2 gene mutation are qualified for molecular testing on the basis
Autor:
Magda A Blaut, Thilo Dörk, Michael Bremer, Natalia Bogdanova, Evgeny N. Imyanitov, Hans Christiansen, Aglaya G. Iyevleva, Svetlana N. Abysheva, Anna P. Sokolenko, Margret Rave-Fränk
Publikováno v:
Breast Cancer Research and Treatment
Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Pat
Autor:
S. Samuel Kim, Marie-Madeleine Dolmans, Zev Rosenwaks, Chii-Ruey Tzeng, Antonio Pellicer, Jacques Donnez, Bunpei Ishizuka, Peter Nagy, Dror Meirow, Claus Yding Andersen, Outi Hovatta, Pedro N. Barri, Pasquale Patrizio, Shuetu Suzuki, Debra A. Gook, Hamish Wallace, Tommaso Falcone, Seok Kim
Publikováno v:
Journal of Assisted Reproduction and Genetics
Fertility issues should be addressed to all patients in reproductive age before cancer treatment. In men, cryopreservation of sperm should be offered to all cancer patients in reproductive age regardless of the risk of gonadal failure. In women, the
Autor:
Qingwei Luo, Roberta De Angelis, Nehmat Houssami, Dianne L. O'Connell, Xue Qin Yu, Clare Kahn
Publikováno v:
BMC Cancer
Background Breast cancer places a heavy burden on the Australian healthcare system, but information about the actual number of women living with breast cancer and their current or future health service needs is limited. We used existing population-ba
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
BMC Cancer
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial c
Autor:
Gilberto Lopes
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in th
Autor:
Ali Al-Zahrani, Taher Al-Tweigeri, Osama Al Malik, Asma Tulbah, Adher Al-Sayed, Said Dermime, Mohamed Alshabanah, Adnan Ezzat, Naser Elkum, Dahish Ajarim
Publikováno v:
BASE-Bielefeld Academic Search Engine
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
Background Breast cancer in young Saudi women is a crucial problem. According to the 2002 annual report of Saudi National Cancer Registry, breast cancers that developed before the age of 40 comprise 26.4% of all female breast cancers comparing to 6.5